Clinical Trials · NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,946
- Start date
- May 2023
- Locations
- 169 sites, 10 countries
- Primary endpoint
- Percent Change from Baseline in Body Weight